Biolegend, 345005, PE anti-human CD366 (Tim-3) Antibody, 25tests

CD366 (Tim-3) is a transmembrane protein also known as T cell immunoglobulin and mucin domain containing protein-3. Tim-3 is expressed at high levels on activated T cells (preferentially on Th1 cells, monocytes/macrophages, and dendritic cells). Tim-3 has also been shown to exist as a soluble protein. Cells expressing Tim-3 are present at high levels in the CNS of animals at the onset of experimental autoimmune encephalomyelitis (EAE), a disease mediated by lymphocytes secreting Th1-like cytokines. Tim-3 has been proposed to inhibit Th1-mediated immune responses and promote immunological tolerance.
25tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human Tim-3 fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Additional reported applications (for relevant formats of this clone) include: costimulation1 (clone 2E2 has been shown to enhance T-cell receptor mediated activation and cytokine secretion) and blocking2,3.
Application References(PubMed link indicates BioLegend citation): Hastings WD, et al. 2009. Eur. J. Immunol. 39:2492. (Costim) Jones RB, et al. 2008. J. Exp. Med. 205:2763. (Block) Klibi J, et al 2009. Blood 113:1957. (FC, Block)
Product Citations: Fang L, et al. 2013. Neuro Oncology. 15:1479. PubMed Ceppi F, et al. 2022. Cancer Immunol Res. 10:856. PubMed Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed Gkika E, et al. 2023. NPJ Precis Oncol. 7:24. PubMed Yan YN, et al. 2023. Mediators Inflamm. 2023:8215567. PubMed Zhang T, et al. 2022. Am J Reprod Immunol. 87:e13524. PubMed Wu L, et al. 2023. Cell Rep Med. 4:100917. PubMed Cheng H, et al. 2023. Nat Metab. 5:314. PubMed Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed Poonia B, Pauza C 2014. PLoS One. 9:88884. PubMed Yang H, et al. 2019. Mol Metab. 23:24. PubMed Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed Ho T, et al. 2016. Blood. 128: 1671 - 1678. PubMed Wang H, et al. 2022. Front Immunol. 13:852436. PubMed Wei F, et al. 2013. Proc Natl Acad Sci U S A. 110:2480. PubMed Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed de Boer B et al. 2018. Cancer cell. 34(4):674-689 . PubMed Sun L, et al. 2020. J Diabetes Res. 2020:2583257. PubMed Su W, et al. 2022. Front Immunol. 13:952338. PubMed Cai D, et al. 2021. Front Mol Biosci. 8:686803. PubMed Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed Andersch L, et al. 2019. BMC Cancer. 19:895. PubMed Zhang Y, et al. 2012. J Leukoc Biol. 91:189. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Houtsma R, et al. 2021. STAR Protoc. 2:100864. PubMed Bhattacharya P, et al. 2020. Elife. 9:00. PubMed Fromentin R, et al. 2016. PLoS Pathog. 12: 1005761. PubMed Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed Jin C, et al. 2016. EMBO Mol Med. 8: 702 - 711. PubMed Barresi V, et al. 2020. J Clin Med. 9:00. PubMed Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed Gorris MAJ, et al. 2018. J Immunol. 200:347. PubMed Finney OC, et al. 2019. J Clin Invest. 130:. PubMed Lake CM, et al. 2021. Cell Death Dis. 12:400. PubMed
RRID: AB_1877236 (BioLegend Cat. No. 345005) AB_2116576 (BioLegend Cat. No. 345006)
Structure: Transmembrane protein containing immunoglobulin domain and mucin-like domain; can exist as a soluble form lacking mucin and transmembrane domains
Distribution: Activated T cells, preferentially on Th1 cells, monocytes, dendritic cells
Function: Plays a role in regulating macrophage activation, T cell apoptosis and immune tolerance
Ligand/Receptor: Galectin-9
Cell Type: Dendritic cells, Monocytes, T cells, Th1, Tregs
Biology Area: Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Hafler DA and Kuchroo V. 2008. J. Exp. Med. 205:2699. 2. Zhu C, et al. 2005. Nat. Immunol. 6:1245. 3. Wang F, et al. 2009. Immunobiology 214:342.
Gene ID: 84868
UniProt: View information about CD366 on UniProt.org
Clone: F38-2E2
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T cell immunoglobulin and mucin domain containing protein 3, hepatitis virus cellular receptor 2, CD366
Isotype: Mouse IgG1, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.